AR038401A1 - Derivados de indazol substituidos como agentes terapeuticos - Google Patents
Derivados de indazol substituidos como agentes terapeuticosInfo
- Publication number
- AR038401A1 AR038401A1 ARP030100372A ARP030100372A AR038401A1 AR 038401 A1 AR038401 A1 AR 038401A1 AR P030100372 A ARP030100372 A AR P030100372A AR P030100372 A ARP030100372 A AR P030100372A AR 038401 A1 AR038401 A1 AR 038401A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- heteroarylalkyl
- heterocycloalkyl
- indazole
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 abstract 1
- MFPSREGPSIUIPQ-UHFFFAOYSA-N 3-(4-fluorophenyl)-1h-indazol-6-amine Chemical compound N=1NC2=CC(N)=CC=C2C=1C1=CC=C(F)C=C1 MFPSREGPSIUIPQ-UHFFFAOYSA-N 0.000 abstract 1
- GXPSEFHENUNPKG-UHFFFAOYSA-N 3-phenyl-1h-indazol-6-amine Chemical compound N=1NC2=CC(N)=CC=C2C=1C1=CC=CC=C1 GXPSEFHENUNPKG-UHFFFAOYSA-N 0.000 abstract 1
- QNQYCNBUNRLHJW-UHFFFAOYSA-N 6-nitro-3-(4-nitrophenyl)-1h-indazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NNC2=CC([N+]([O-])=O)=CC=C12 QNQYCNBUNRLHJW-UHFFFAOYSA-N 0.000 abstract 1
- MXIWPBDHLNPTQI-UHFFFAOYSA-N 6-nitro-3-phenyl-1h-indazole Chemical compound N=1NC2=CC([N+](=O)[O-])=CC=C2C=1C1=CC=CC=C1 MXIWPBDHLNPTQI-UHFFFAOYSA-N 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002473 indoazoles Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de indazol substituidos como agentes terapéuticos en forma de una base libre o una sal farmacéuticamente aceptable, solvato o un solvato de la sal del mismo, un procedimiento para su preparación, formulaciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos en terapia. Reivindicación 1: Un compuesto de fórmula (1) en la cual R1 es arilo o heteroarilo cada uno de los cuales está opcionalmente substituido con una o más de los siguientes R3, -OR3, -OCOR3, -COOR3, -COR3, -CONR3R4, -NHCOR3, -NR3R4, -NHSO2R3, -SO2R3, -SO2NR3R4, -SR3, CN, halógeno o NO2, R2 es NO2, NH2, -NR5R6 o -NR6R7; R3 y R4 son cada uno independientemente H, alquilo C1-6, alquenilo C2-6(C3-8cicloalquilo)alquilo C0-6, fluoralquilo C1-6, heterocicloalquilo C0-6, heteroariloalquilo C0-6; y dicho alquilo C1-6, alquenilo C2-6, (cicloalquilo C3-8)alquiloC0-6, fluoralquilo C1-6, heterocicloalquilo C0-6, heteroariloalquilo C0-6 pueden estar substituidos con uno o más B; o R3 o R4 forman conjuntamente un anillo heterocíclico de 5, 6 o 7 miembros que contienen 1 a 4 heteroátomos independientemente seleccionados entre N, O y S, y dicho anillo puede estar opcionalmente substituido con uno o más B; B es R10, -COOR10, -COR10, -NHCOR10, -NR10R11, -CONR10R11, -OR10, -SO2NR10R11, CN, halógeno u oxo; R5 es fenilo o heteroarilo cada uno de los cuales están opcionalmente substituido con uno o más de R10, -OR10, -OCOR10, -COOR10, -CONR10R11, -NHCOR10, -NR10R11, -NHSO2R10, -SO2R10, -SO2NR10R11, -SR10, CN, halógeno, o NO2, R6 es H, alquilo C1-6, heterociclo alquilo C0-6, o hidroxi alquilo C1-6; R7 es alquilo C1-6, (cicloalquilo C3-8)alquilo C0-6, cicloalquenilo C5-8 alquilo C0-6 o R5alquilo C1-6; A es H, R8, -OR8, -OCOR8, -COOR8, -CONR8R9, -NHCOR8, -NR8R9, -NHSO2R8, -SO2R8, -SO2NR8R9, -SR8, CN, halógeno, heterocicloalquilo C0-6 o heteroarilalquilo C0-6; R8 y R9 son cada uno independientemente H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, heterocicloalquilo C0-6, heteroariloalquilo C0-6, y dichos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, heterocicloalquilo C0-6 o heteroariloalquilo C0-6 pueden estar substituidos con uno o más B; o R8 y R9 forman conjuntamente un anillo heterocíclico de 5, 6 o 7 miembros que contiene 1 a 4 heteroátomos independientemente seleccionados entre N, O y S, y dicho anillo puede estar sustituido con uno o más B; R10 y R11 cada uno independientemente son H, alquilo C1-6, fluoralquilo C1-6 o hidroxialquilo C1-6; o R10 y R11 forman conjuntamente un anillo heterocíclico de 5, 6 o 7 miembros que contienen 1 a 4 heteroátomos independientemente seleccionados entre N, O y S y dicho anillo puede estar sustituido con uno o más B; con la condición que dicho compuesto no es 6-amino-3-(4-fluorfenil)-indazol, 6-amino-3-fenil-indazol, 6-nitro-3-fenil-indazol, 6-nitro-3-(4-nitrofenil)-indazol y que dichos compuestos no tienen una quinazolina en posición R5, como base libre o sal del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200450A SE0200450D0 (sv) | 2002-02-13 | 2002-02-13 | Therapeutic agents |
| SE0203122A SE0203122D0 (sv) | 2002-10-22 | 2002-10-22 | New Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038401A1 true AR038401A1 (es) | 2005-01-12 |
Family
ID=27736683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100372A AR038401A1 (es) | 2002-02-13 | 2003-02-06 | Derivados de indazol substituidos como agentes terapeuticos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050113370A1 (es) |
| EP (1) | EP1476432A1 (es) |
| JP (1) | JP2005519074A (es) |
| AR (1) | AR038401A1 (es) |
| AU (1) | AU2003206343A1 (es) |
| TW (1) | TW200302722A (es) |
| WO (1) | WO2003068754A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10037759A1 (de) * | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
| US20040077702A1 (en) * | 2001-09-14 | 2004-04-22 | Wen-Mei Fu | Treatment of nuerodegenerative diseases |
| US7166293B2 (en) * | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
| AU2003259749A1 (en) | 2002-08-12 | 2004-02-25 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
| AP2006003700A0 (en) | 2004-02-13 | 2006-08-31 | Warner Lambert Co | Androgen receptor modulators |
| WO2005085249A1 (en) | 2004-02-27 | 2005-09-15 | F. Hoffmann-La Roche Ag | Fused derivatives of pyrazole |
| AU2005219517A1 (en) | 2004-02-27 | 2005-09-15 | F.Hoffmann-La Roche Ag | Heteroaryl-fused pyrazolo derivatives |
| RU2006134022A (ru) | 2004-02-27 | 2008-04-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные индазола и содержащие их фармацевтические композиции |
| KR20060043654A (ko) * | 2004-03-15 | 2006-05-15 | 융신 파마슈티칼 인더스트리얼 컴파니 리미티드 | 향염증성 사이토카인 방출의 우선적 억제 |
| US7378532B2 (en) | 2004-03-26 | 2008-05-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Fused pyrazolyl compound |
| CA2563291A1 (en) | 2004-04-13 | 2005-10-27 | Warner-Lambert Company Llc | 4-cyano-phenoxy-alkyl carboxyl derivatives as androgen modulators |
| JP2007533726A (ja) | 2004-04-22 | 2007-11-22 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アンドロゲンモジュレーター |
| WO2005118543A1 (ja) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
| BRPI0513020A (pt) | 2004-07-08 | 2008-04-22 | Warner Lambert Co | moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| WO2006130090A1 (en) * | 2005-06-03 | 2006-12-07 | Pronas Pharma Ab | Use of a substance which inhibits endothelin type b and 5-hydroxytryptamine type 1b receptor upregulation in the treatment of ischemic disorders |
| JP2009506007A (ja) | 2005-08-25 | 2009-02-12 | エフ．ホフマン−ラ ロシュ アーゲー | ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法 |
| KR101152162B1 (ko) | 2006-12-08 | 2012-07-10 | 에프. 호프만-라 로슈 아게 | 치환된 피리미딘 및 ｊｎｋ 조절제로서 그의 용도 |
| EP2671885A1 (en) * | 2012-06-05 | 2013-12-11 | Ares Trading S.A. | Imidazo-oxadiazole and Imidazo-thiadiazole derivatives |
| IL259810A (en) * | 2018-06-04 | 2018-07-31 | Yeda Res & Dev | Mitogen-activated protein kinase kinase 7 inhibitors |
| CN119504547A (zh) * | 2025-01-21 | 2025-02-25 | 山东安弘制药有限公司 | 一种氨磺必利的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982000824A1 (en) * | 1980-09-05 | 1982-03-18 | Geissmann F | 1h and 2h indazol derivatives and medicaments containing them |
| US5185350A (en) * | 1991-09-23 | 1993-02-09 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted pyridinylamino-1h-indoles,1h-indazoles,2h-indazoles, benzo (b)thiophenes and 1,2-benzisothiazoles |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US6982274B2 (en) * | 2001-04-16 | 2006-01-03 | Eisai Co., Ltd. | 1H-indazole compound |
| JP2004536113A (ja) * | 2001-07-03 | 2004-12-02 | カイロン コーポレイション | チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物 |
-
2003
- 2003-01-30 TW TW092102242A patent/TW200302722A/zh unknown
- 2003-02-06 AR ARP030100372A patent/AR038401A1/es not_active Application Discontinuation
- 2003-02-11 AU AU2003206343A patent/AU2003206343A1/en not_active Abandoned
- 2003-02-11 WO PCT/SE2003/000227 patent/WO2003068754A1/en not_active Application Discontinuation
- 2003-02-11 JP JP2003567885A patent/JP2005519074A/ja active Pending
- 2003-02-11 US US10/504,411 patent/US20050113370A1/en not_active Abandoned
- 2003-02-11 EP EP03703636A patent/EP1476432A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20050113370A1 (en) | 2005-05-26 |
| AU2003206343A1 (en) | 2003-09-04 |
| JP2005519074A (ja) | 2005-06-30 |
| TW200302722A (en) | 2003-08-16 |
| EP1476432A1 (en) | 2004-11-17 |
| WO2003068754A1 (en) | 2003-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038401A1 (es) | Derivados de indazol substituidos como agentes terapeuticos | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
| AR036103A1 (es) | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| AR040477A1 (es) | Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos | |
| CO2022001853A2 (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| ES2093367T3 (es) | Derivados de quinazolina. | |
| UY29177A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos | |
| AR077468A1 (es) | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa | |
| AR054799A1 (es) | Derivados de oxindol | |
| MXPA06002880A (es) | Derivados 1,1,1-trifluoro-4-fenil-4-metil-2-(1h-pirrolo `2,3-cipiridin-2-ilmetil) pentan-2-ol y compuestos relacionados como ligandos glucorticoides para el tratamiento de enfermedades inflamatorias y diabetes. | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| PE20060299A1 (es) | DIFENILIMIDAZOPIRIMIDINA E -IMIDAZOL AMINAS COMO INHIBIDORES DE ß-SECRETASA | |
| PE20050664A1 (es) | Derivados de 1h-imidazo[4,5-c]quinolina | |
| UY28150A1 (es) | Agentes terapeuticos | |
| CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
| AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
| PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
| AR065531A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas. | |
| AR043181A1 (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |